Anika Therapeutics (ANIK) Other Non-Current Liabilities (2010 - 2026)
Anika Therapeutics (ANIK) reported Other Non-Current Liabilities of $726000.0 for Q1 2026, down 2.42% year-over-year from $744000.0 in Q1 2025, and up 3.57% quarter-over-quarter from $701000.0 in Q4 2025.
Anika Therapeutics (ANIK) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 17 years of Other Non-Current Liabilities data on file, last reported at $726000.0 in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $726000.0, down 2.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $726000.0 (down 2.42% YoY), and the FY2025 annual result was $701000.0, down 9.2% from the prior year.
- Other Non-Current Liabilities climbed to $726000.0 in Q1 2026 per ANIK's latest filing, from $701000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $806000.0 in Q3 2024 and troughed at $398000.0 in Q4 2022.
- A 5-year average of $577882.4 and a median of $587000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities slumped 96.53% in 2022, then jumped 101.5% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $398000.0 in 2022, then gained by 1.51% to $404000.0 in 2023, then jumped by 91.09% to $772000.0 in 2024, then decreased by 9.2% to $701000.0 in 2025, then advanced by 3.57% to $726000.0 in 2026.
- Business Quant data shows ANIK's Other Non-Current Liabilities at $726000.0 in Q1 2026, $701000.0 in Q4 2025, and $761000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Anika Therapeutics | 197.89 Mn | 131.10 Mn | 19.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 726,000.00 |
| Dec 31, 2025 | 701,000.00 |
| Sep 30, 2025 | 761,000.00 |
| Jun 30, 2025 | 756,000.00 |
| Mar 31, 2025 | 744,000.00 |
| Dec 31, 2024 | 772,000.00 |
| Sep 30, 2024 | 806,000.00 |
| Jun 30, 2024 | 407,000.00 |
| Mar 31, 2024 | 404,000.00 |
| Dec 31, 2023 | 404,000.00 |
| Sep 30, 2023 | 400,000.00 |
| Jun 30, 2023 | 401,000.00 |
| Mar 31, 2023 | 399,000.00 |
| Dec 31, 2022 | 398,000.00 |
| Sep 30, 2022 | 474,000.00 |
| Jun 30, 2022 | 587,000.00 |
| Mar 31, 2022 | 684,000.00 |
| Dec 31, 2021 | 1.26 Mn |
| Jun 30, 2021 | 16.90 Mn |
| Mar 31, 2021 | 1.58 Mn |